Table 6 Comparison of PFS in patients receiving T-DM1 with or without prior treatment with taxane-trastuzumab-pertuzumab
Characteristics | No prior pertuzumab n = 34 | Prior pertuzumab n = 17 | Total n = 51 |
|---|---|---|---|
Progression | |||
No | 7 (20.6%) | 3 (17.6%) | 10 (19.60%) |
Yes | 27 (79.4%) | 14 (82.4%) | 41 (80.4%) |
PFS according to Kaplan-Meier (months) | |||
Median | 9.50 | 3.55 | 9.01 |
CI95 | (6.15–12.26) | (2.27–11.38) | (4.87–11.41) |
Minimum | 1.7 | 1.1 | 1.1 |
Maximum | 55.4 | 21.4 | 55.5 |
Intergroup comparison (Log-Rank test) | |||
p-value | 0.144 | ||